Previous 10 | Next 10 |
David Abrams’ 13F portfolio value decreased this quarter from $4.56B to $4.28B. The number of positions remained steady at 18. Abrams Capital Management increased Coupang and Cantaloupe while reducing AMERCO during the quarter. The top three positions are Lithia Motors, Alp...
Seth Klarman’s 13F portfolio value decreased from $10.13B to $9.30B this quarter. Baupost Group increased Fiserv, Dropbox, Encompass Health, Nuvation Bio, and ironSource while reducing Joby Aviation and dropping Pershing Square Tontine and NortonLifeLock. The portfolio cont...
Nuvation Bio press release (NYSE:NUVB): Q1 GAAP EPS of -$0.10 beats by $0.04. The company is on track to select its first clinical candidate for the DDC program by the end of 2022. For further details see: Nuvation Bio GAAP EPS of -$0.10 beats by $0.04
NUV-422 on track for initiation of multiple Phase 1b combination and Phase 2 monotherapy cohorts by the end of 2022 First patient dosed in Phase 1 study of NUV-868 for the treatment of solid tumors On track to select first clinical candidate from Drug-Drug Conjugate (D...
Nuvation Bio press release (NYSE:NUVB): Q4 GAAP EPS of -$0.12 in-line. Strong balance sheet with cash, cash equivalents and marketable securities of $765.4 million as of December 31, 2021. For further details see: Nuvation Bio GAAP EPS of -$0.12 in-line
FDA Fast Track Designation and multiple IND applications accepted for lead candidate NUV-422 Multiple milestones expected in 2022 for broad pipeline of potential product candidates Strong balance sheet with cash, cash equivalents and marketable securities of $765.4 mil...
David Abrams’ 13F portfolio value decreased marginally this quarter from $4.59B to $4.56B. The number of positions remained steady at 18. Abrams Capital Management increased Coupang while reducing AMERCO during the quarter. The top three positions are Lithia Motors, Alphabe...
Seth Klarman’s 13F portfolio value decreased from $10.88B to $10.13B this quarter. Baupost Group added Fiserv while dropping eBay and International Flavors & Fragrances. The portfolio continues to be heavily concentrated with the top three positions accounting for ~35% ...
Nuvation Bio Announces FDA Clearance of Investigational New Drug Application for NUV-868 for the Treatment of Advanced Solid Tumors PR Newswire NEW YORK , Jan. 20, 2022 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some...
Nuvation Bio Provides Corporate Update and Highlights Key 2022 Milestones PR Newswire David Hung , M.D., founder, president, and chief executive officer, to present virtually at the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022 at 7:30 a.m...
News, Short Squeeze, Breakout and More Instantly...
Nuvation Bio Inc. Class A Company Name:
NUVB Stock Symbol:
NYSE Market:
Nuvation Bio Inc. Class A Website:
Tumors shrank in 91% of taletrectinib-treated patients with advanced ROS1-positive NSCLC who were ROS1 TKI-naïve and 52% of those who were ROS1 TKI-pretreated in the study Responses were durable with long-term follow-up; 71% of TKI-naïve patients were still progression-free at t...
Nuvation Bio Inc. (NYSE: NUVB), a late clinical-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, announced today that David Hung, M.D., Founder, President, and Chief Executive Officer of Nu...
Acquisition of AnHeart Therapeutics transformed Nuvation Bio into a late-stage, global oncology company with potential to become a commercial organization by the end of 2025 Updated data from the pivotal Phase 2 TRUST-I clinical study of taletrectinib, a ROS1 inhibitor, to be presented at...